mirtazapine has been researched along with Breast Neoplasms in 1 studies
Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.
Breast Neoplasms: Tumors or cancer of the human BREAST.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Background We examined the efficacy of mirtazapine in preventing delayed nausea and vomiting following highly emetogenic chemotherapy (HEC)." | 9.34 | Mirtazapine, a dopamine receptor inhibitor, as a secondary prophylactic for delayed nausea and vomiting following highly emetogenic chemotherapy: an open label, randomized, multicenter phase III trial. ( Cao, J; Hu, X; Ouyang, Q; Ragaz, J; Shao, Z; Teng, Y; Wang, B; Wang, L; Wang, S; Wang, X; Wang, Z; Wu, J; Zhang, J, 2020) |
| "Background We examined the efficacy of mirtazapine in preventing delayed nausea and vomiting following highly emetogenic chemotherapy (HEC)." | 5.34 | Mirtazapine, a dopamine receptor inhibitor, as a secondary prophylactic for delayed nausea and vomiting following highly emetogenic chemotherapy: an open label, randomized, multicenter phase III trial. ( Cao, J; Hu, X; Ouyang, Q; Ragaz, J; Shao, Z; Teng, Y; Wang, B; Wang, L; Wang, S; Wang, X; Wang, Z; Wu, J; Zhang, J, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, J | 1 |
| Ouyang, Q | 1 |
| Wang, S | 1 |
| Ragaz, J | 1 |
| Wang, X | 1 |
| Teng, Y | 1 |
| Wang, B | 1 |
| Wang, Z | 1 |
| Zhang, J | 1 |
| Wang, L | 1 |
| Wu, J | 1 |
| Shao, Z | 1 |
| Hu, X | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase III Trial Comparing Dexamethasone, Aprepitant With or Without Mirtazapine in Delayed Emesis Control and Appetite Improvement[NCT02336750] | Phase 3 | 212 participants (Actual) | Interventional | 2014-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for mirtazapine and Breast Neoplasms
| Article | Year |
|---|---|
Mirtazapine, a dopamine receptor inhibitor, as a secondary prophylactic for delayed nausea and vomiting following highly emetogenic chemotherapy: an open label, randomized, multicenter phase III trial.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Cisplatin | 2020 |